Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Edesa Biotech (EDSA) Income from Continuing Operations (2016 - 2022)

Edesa Biotech's Income from Continuing Operations history spans 10 years, with the latest figure at 2813911.0 for Q3 2022.

  • For Q3 2022, Income from Continuing Operations rose 23.66% year-over-year to 2813911.0; the TTM value through Sep 2022 reached 18318837.0, down 37.29%, while the annual FY2025 figure was 7185523.0, 16.46% down from the prior year.
  • Income from Continuing Operations for Q3 2022 was 2813911.0 at Edesa Biotech, up from 5780007.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 364849.0 in Q4 2018 and bottomed at 5780007.0 in Q2 2022.
  • The 5-year median for Income from Continuing Operations is 2012875.0 (2020), against an average of 2556896.33.
  • The largest annual shift saw Income from Continuing Operations soared 73.95% in 2018 before it crashed 199.94% in 2019.
  • A 5-year view of Income from Continuing Operations shows it stood at 364849.0 in 2018, then plummeted by 199.94% to 1094333.0 in 2019, then crashed by 141.02% to 2637612.0 in 2020, then crashed by 95.46% to 5155603.0 in 2021, then soared by 45.42% to 2813911.0 in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Income from Continuing Operations are 2813911.0 (Q3 2022), 5780007.0 (Q2 2022), and 4569316.0 (Q1 2022).